rucaparib (Rubraca)
Jump to navigation
Jump to search
Indications
- deleterious BRCA mutation associated advanced ovarian cancer in patients treated with >= 2 chemotherapies[1]
- androgen-independent metastatic prostate cancer
Dosage
Tablets: 300 mg
Adverse effects
- fatigue (including asthenia),
- nausea, vomiting, abdominal pain, dysgeusia, constipation, decreased appetite, diarrhea
- dyspnea
- anemia, thrombocytopenia
- myelodysplastic syndrome/acute myeloid leukemia (0.5%)[1]
- hepatotoxicity[2]
Laboratory
- companion diagnostic test identifies alterations in BRCA1 & BRCA2 genes in ovarian tumor tissue
Mechanism of action
- inhibits poly ADP ribose polymerase (PARP inhibitor)
More general terms
References
- ↑ 1.0 1.1 1.2 FDA: Drugs: Rucaparib. December 19, 2016 http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm533891.htm
- ↑ 2.0 2.1 Bankhead C Another Win for PARP Inhibition in Ovarian Cancer Rucaparib maintenance extends PFS in all subgroups. MedPage Today. September 11, 2017 https://www.medpagetoday.com/MeetingCoverage/ESMO/67807
Database
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=9931954
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=9931953
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=121490161
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=76021631
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=53356947
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=69552145
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=69552812
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=69871957